ZOMDF on OTC

Zomedica Corp.

Canadian pharmaceutical preparations company, incorporated in Alberta. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Arcus Biosciences, Verastem Oncology or Foghorn Therapeutics Inc., or pick any stock.

  • TickerZOMDF on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersAnn Arbor, Michigan1
  • Incorporated inAlberta, Canada2
  • Business address1101 Technology Drive, Suite 100, Ann Arbor, Mi 481082
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Zomedica Corp. (“Zomedica” or the “Company”) was incorporated on January 7, 2013 under the Business Corporations Act (Alberta) as Wise Oakwood Ventures Inc. (“WOW”) and was classified as a capital pool company, as defined in Policy 2.4 of the TSX Venture Exchange. ZoMedica Pharmaceuticals Inc. (“ZoMedica”) was incorporated on May 14, 2015, under the Canada Business Corporations Act.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

67.7%Gross margin4
-263.4%Operating margin4
-255.6%Net margin4
17.4%Revenue growth, 20254
-70.9%Return on equity4
-$18.2MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Consumables Revenue brought in 65% of the revenue Zomedica Corp. broke down this way in fiscal 2025.

  1. Consumables Revenue$20.7M465%up 17% from 2024
  2. Capital Revenue$9.3M429%down 3% from 2024
  3. Engineering Revenue$2.0M46%
  4. Product and Service, Other$123.0K40%down 6% from 2024
Products and services by year
Products and services20242025
Consumables Revenue$17.7M$20.7M
Capital Revenue$9.5M$9.3M
Engineering Revenue$2.0M
Product and Service, Other$131.0K$123.0K

Business segments

Therapeutic brought in 82% of the revenue Zomedica Corp. broke down this way in fiscal 2025.

  1. Therapeutic$26.2M482%up 5% from 2024
  2. Development Services$3.0M49%
  3. Diagnostics$2.8M49%up 15% from 2024
Business segments by year
Business segments20242025
Therapeutic$24.9M$26.2M
Development Services$3.0M
Diagnostics$2.4M$2.8M

Regions

United States brought in 83% of the revenue Zomedica Corp. broke down this way in fiscal 2025.

  1. United States$26.5M483%up 17% from 2024
  2. Outside the United States$5.6M417%up 18% from 2024
Regions by year
Regions20242025
United States$22.6M$26.5M
Outside the United States$4.7M$5.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue32¢$10.4M
  • Research and development22¢$7.2M
  • Other costs44¢$14.2M
  • Income tax1¢$278.0K

Out of $32.0M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$32.0M in 2025
0$10.0M$20.0M$30.0M$40.0M2020: $0$020202021: $4.1M$4.1M20212022: $18.9M$18.9M2022+358%2023: $25.2M$25.2M2023+33%2024: $27.3M$27.3M2024+8%2025: $32.0M$32.0M2025+17%
Gross profit56784$21.7M in 2025
0$10.0M$20.0M$30.0M2020: $0$020202021: $3.1M$3.1M20212022: $13.5M$13.5M2022+341%2023: $17.3M$17.3M2023+29%2024: $19.1M$19.1M2024+10%2025: $21.7M$21.7M2025+14%
Operating income956784-$84.4M in 2025+326% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$19.8M-$19.8M20192020: -$16.8M-$16.8M2020−15%2021: -$21.4M-$21.4M2021+27%2022: -$21.9M-$21.9M2022+3%2023: -$43.3M-$43.3M2023+97%2024: -$51.1M-$51.1M2024+18%2025: -$84.4M-$84.4M2025+65%
Net income956784-$81.9M in 2025+314% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$19.8M-$19.8M20192020: -$16.9M-$16.9M2020−15%2021: -$18.4M-$18.4M2021+9%2022: -$17.0M-$17.0M2022−7%2023: -$34.5M-$34.5M2023+103%2024: -$47.0M-$47.0M2024+36%2025: -$81.9M-$81.9M2025+74%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Net revenue$32.0M$27.3M
Cost of revenue$10.4M$8.2M
Gross profit$21.7M$19.1M
General and administrative$24.5M$29.7M
Research and development$7.2M$7.3M
Selling and marketing$18.5M$17.2M
Impairment expense$55.8M$16.0M
Loss from operations-$84.4M-$51.1M
Interest income$2.4M$4.0M
Loss on disposal of assets-$68.0K-$210.0K
Other (expense) income-$144.0K$10.0K
Foreign exchange loss-$6.0K-$252.0K
Loss before income taxes-$82.1M-$47.5M
Income tax benefit-$278.0K-$557.0K
Net loss-$81.9M-$47.0M
Unrealized (loss) gain, change in fair value of available-for-sale securities, net of tax-$2.0K$132.0K
Change in foreign currency translation$74.0K-$92.0K
Net loss and comprehensive loss-$81.8M-$46.9M
Weighted average number of common shares - basic (in shares)979.9M shares979.9M shares
Weighted average number of common shares - diluted (in shares)979.9M shares979.9M shares
Loss per share - basic (in dollars per share)-$0.08-$0.05
Loss per share - diluted (in dollars per share)-$0.08-$0.05

Compare Zomedica Corp. with another company

Leadership

Who has led Zomedica Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gerald Solensky Jr.2017–2019
  2. Rampertab Shameze2020
  3. Larry C. Heaton Ii.2022–now

President

  1. Gerald Solensky Jr.2017–2019
  2. Stephanie Morley2019–2021
  3. Larry C. Heaton Ii.2021

Chief financial officer

  1. Rampertab Shameze2017–2020
  2. Ann Cotter2020–2021
  3. Peter Donato2023–2024
  4. Scott Jordan2025–now

Chief operating officer

  1. Stephanie Morley2017–2020
  2. Anthony K. Blair2022–now
20202025
Board members and other officers (18)

Former names

  • Zomedica Pharmaceuticals Corp.Sep 8, 2016 to Sep 28, 20202

Timeline

  1. Oct 6, 2022New chief executive Larry C. Heaton Ii. becomes CEO12
  2. Mar 17, 2020New chief executive Rampertab Shameze becomes CEO13
  3. Nov 21, 2017New chief executive Gerald Solensky Jr. becomes CEO14

Filings

204 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 52 major events, 100 insider forms, 32 other. The latest 20:

  1. Aug 7, 20264 PRIMARY DOCUMENT EDGAR
  2. Aug 7, 20264 PRIMARY DOCUMENT EDGAR
  3. Aug 7, 20264 PRIMARY DOCUMENT EDGAR
  4. Aug 5, 20268-K EDGAR
  5. Aug 5, 202610-Q EDGAR
  6. Jun 11, 20268-K EDGAR
  7. May 26, 20264 EDGAR
  8. May 21, 20264 EDGAR
  9. May 21, 20264 EDGAR
  10. May 14, 20264 EDGAR
  11. May 11, 20264 EDGAR
  12. May 8, 20264 EDGAR
  13. May 6, 20268-K EDGAR
  14. May 6, 202610-Q EDGAR
  15. Apr 27, 2026DEF 14A EDGAR
  16. Apr 24, 2026DEFA14A DEFA 14A EDGAR
  17. Apr 14, 2026PRE 14A EDGAR
  18. Mar 16, 20268-K EDGAR
  19. Mar 16, 202610-K EDGAR
  20. Nov 18, 20254 PRIMARY DOCUMENT EDGAR

The 204 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

57 open-market trades by officers, directors and large owners since October 2021: 57 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 21, 2026Klass Russell KevinSr Vice President, SalesBuy104,000$0.10$10.4KForm 4
May 21, 2026Klass Russell KevinSr Vice President, SalesBuy16,899$0.11$1.9KForm 4
May 20, 2026POWERS JOHNNY DDirectorBuy97,515$0.10$9.8KForm 4
May 20, 2026Klass Russell KevinSr Vice President, SalesBuy200,000$0.11$22.0KForm 4
May 19, 2026POWERS JOHNNY DDirectorBuy2,485$0.10$248Form 4
May 18, 2026POWERS JOHNNY DDirectorBuy100,000$0.10$10.0KForm 4
May 13, 2026POWERS JOHNNY DDirectorBuy200,000$0.11$22.0KForm 4
May 12, 2026POWERS JOHNNY DDirectorBuy100,000$0.11$11.0KForm 4
May 11, 2026POWERS JOHNNY DDirectorBuy391,129$0.11$43.0KForm 4
May 8, 2026POWERS JOHNNY DDirectorBuy108,871$0.11$12.0KForm 4
May 8, 2026HEATON LARRY C IICEOBuy250,000$0.11$27.5KForm 4
Nov 13, 2025Klass Russell KevinSr Vice President, SalesBuy150,000$0.10$15.0KForm 4
Nov 10, 2025Klass Russell KevinSr Vice President, SalesBuy120,000$0.10$12.0KForm 4
Nov 7, 2025Klass Russell KevinSr Vice President, SalesBuy5,000$0.10$500Form 4
Nov 6, 2025Klass Russell KevinSr Vice President, SalesBuy253,007$0.08$20.2KForm 4
Aug 12, 2025Klass Russell KevinSr Vice President, SalesBuy995,341$0.04$39.8KForm 4
Aug 11, 2025Klass Russell KevinSr Vice President, SalesBuy60,723$0.04$2.4KForm 4
Aug 11, 2025Klass Russell KevinSr Vice President, SalesBuy500,000$0.04$20.0KForm 4
Aug 8, 2025Klass Russell KevinSr Vice President, SalesBuy500,000$0.04$20.0KForm 4
May 21, 2025Blair Anthony KCOOBuy100,000$0.05$5.0KForm 4

All 57 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ancora Advisors LLC83,610$8.4K0.0%No change
CoreCap Advisors, LLC4,800$4800.0%No change
Gill Capital Partners, LLC2,719$2720.0%No change
Harbour Investments, Inc.2,200$2200.0%No change
EverSource Wealth Advisors, LLC1,000$1000.0%New
Bogart Wealth, LLC680$680.0%No change
Farther Finance Advisors, LLC86$90.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38